Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.0(2,11).0( 4,9)]-hexadeca-2(11)3,5,7,9-pentaene

Details for Australian Patent Application No. 2002351008 (hide)

Owner Pfizer Products Inc.

Inventors Am Ende, Mary Tanya; Moses, Sara Kristen; Waterman, Kenneth Craig; Roy, Michael Christopher; Quan, Ernest Shing; Smith, Scott Wendell

Agent Shelston IP

Pub. Number AU-B-2002351008

PCT Number PCT/IB02/04612

PCT Pub. Number WO2003/045437

Priority 60/334,652 30.11.01 US

Filing date 4 November 2002

Wipo publication date 10 June 2003

Acceptance publication date 12 July 2007

International Classifications

A61K 9/22 (2006.01) Medicinal preparations characterised by special physical form - Sustained or differential release type

A61K 9/20 (2006.01) Medicinal preparations characterised by special physical form - Pills, lozenges or tablets

A61K 9/26 (2006.01) Medicinal preparations characterised by special physical form - Discrete particles in supporting matrix

A61K 9/28 (2006.01) Medicinal preparations characterised by special physical form - Dragees

A61K 31/495 (2006.01) - having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine

A61K 31/4985 (2006.01) - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems

A61K 47/02 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - Inorganic compounds

A61K 47/10 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - Alcohols

A61K 47/34 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds

A61K 47/36 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - Polysaccharides

A61K 47/38 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - Cellulose

A61P 1/00 (2006.01) Drugs for disorders of the alimentary tract or the digestive system

A61P 1/04 (2006.01) Drugs for disorders of the alimentary tract or the digestive system

A61P 3/04 (2006.01) Drugs for disorders of the metabolism

A61P 9/00 (2006.01) Drugs for disorders of the cardiovascular system

A61P 9/10 (2006.01) Drugs for disorders of the cardiovascular system

A61P 9/12 (2006.01) Drugs for disorders of the cardiovascular system

A61P 25/02 (2006.01) Drugs for disorders of the nervous system

A61P 25/06 (2006.01) Drugs for disorders of the nervous system

A61P 25/14 (2006.01) Drugs for disorders of the nervous system

A61P 25/16 (2006.01) Drugs for disorders of the nervous system

A61P 25/18 (2006.01) Drugs for disorders of the nervous system

A61P 25/20 (2006.01) Drugs for disorders of the nervous system

A61P 25/22 (2006.01) Drugs for disorders of the nervous system

Event Publications

20 March 2003 Complete Application Filed

  Priority application(s): 60/334,652 30.11.01 US

21 August 2003 Application Open to Public Inspection

  Published as AU-B-2002351008

12 July 2007 Application Accepted

  Published as AU-B-2002351008

26 July 2007 Application for Amendment

  The nature of the amendment is: Amend the invention title to read Pharmaceutical compositions of 5,8,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pe ntaene. Address for service in Australia - Shelston IP Level 21 60 Margaret Street Sydney NSW 2000

8 November 2007 Amendment Made

  The nature of the amendment is: Amend the invention title to read Pharmaceutical compositions of 5,8,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pe ntaene

29 November 2007 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2002351009-NUCLEIC ACIDS ENCODING PROTEASES

2002351007-NUCLEIC ACIDS ENCODING VERY LONG CHAIN FATTY ACID BIOSYNTHESIS ENZYMES